Cancer BiologybioRxivPreprint
Targeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha.
Kirsty Hodgson, Joseph Inns, Gary Reynolds…·Neil Rajan
This study identifies non-canonical NF-κB signalling as a therapeutic target in CYLD cutaneous syndrome and shows that IKK inhibition reduces tumor viability in patient-derived models.
3 citations